Valsartan Hydrochlorothiazide Tablets

This product is a compound preparation, and its components are: each tablet contains 80 mg of valsartan and 12.5 mg of amiloride.

?This product is a film-coated tablet, which appears white or off-white after removing the film coating.

Oral administration, 1 tablet at a time, once a day. The maximum antihypertensive effect can be achieved within 2-4 weeks of medication. See the instructions for details.

In two controlled clinical trials involving a total of 1,570 patients, 730 patients received the combination of valsartan and hydrochlorothiazide, and the adverse events reported were as follows: Central nervous system Common (5%): headache (10.8%: placebo 17.2%), dizziness. Occasional (5-0.1%): fatigue, depression. Upper respiratory tract Occasional (5-0.1%): cough, rhinitis, sinusitis, pharyngitis, upper respiratory tract infection, nosebleed. Gastrointestinal tract Occasional (5-0.1%): nausea, diarrhea, indigestion, abdominal pain. Lower urinary tract Occasional (5-0.1%): frequent urination, urinary tract infection. Musculoskeletal system Occasional (5-0.1%): pain in the arms or legs, arthritis, myalgia, sprains and strains, muscle spasms. Other Occasional (5-0.1%): None

1. Contraindicated if allergic to valsartan hydrochlorothiazide, other sulfonamides or any of the ingredients in this product. 2. Contraindicated if pregnant (see pregnancy and lactation). 3. Contraindicated if severe liver damage, biliary cirrhosis or cholestasis. 4. Contraindicated if severe renal failure (creatinine clearance <30mLmin) or anuria. 5. Contraindicated if refractory hypokalemia, hyponatremia or hypercalcemia and symptomatic hyperuricemia.

Precautions for children: There is insufficient research data on the therapeutic application of this product in children. Precautions for pregnancy and lactation: Prevented women from taking this product. Precautions for the elderly: Not clear yet.

Combination with other antihypertensive drugs can increase the antihypertensive effect of this product. When used in combination with potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes, or other drugs that increase serum potassium (such as heparin), caution should be exercised and serum potassium levels should be monitored. It has been reported that the simultaneous use of lithium, ACE inhibitors and/or thiazide diuretics can cause reversible increases in serum potassium concentrations and lithium poisoning. There is no experience in the simultaneous use of valsartan and lithium. Therefore, it is recommended to regularly monitor serum lithium levels when lithium and this product are used in combination. No clinically significant interactions have been observed between valsartan alone and any of the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine and glibenclamide. Because this product contains thiazide diuretics

seal.

7s

24 months

Shaanxi Bai LU Pharmaceutical Co., Ltd.

• Founded in:

  2000-12-28

• Address:

  Lingqian Town, Sanyuan County, Xianyang City, Shaanxi Province

• Tax NO.:

  91610000719707197J

• Registered Funds:

  50 million yuan

• Email:

  Log in to view